A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.
A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.
复制标题
DOI：
10.3390/microorganisms9040806
复制
发表时间：
2021-04-11
期刊：
影响因子：
4.5
通讯作者：
Dimopoulos MA
中科院分区：
文献类型：
--
作者：
Pappa V;Bouchla A;Terpos E;Thomopoulos TP;Rosati M;Stellas D;Antoniadou A;Mentis A;Papageorgiou SG;Politou M;Kotanidou A;Kalomenidis I;Poulakou G;Jahaj E;Korompoki E;Grigoropoulou S;Hu X;Bear J;Karaliota S;Burns R;Pagoni M;Trontzas I;Grouzi E;Labropoulou S;Stamoulis K;Bamias A;Tsiodras S;Felber BK;Pavlakis GN;Dimopoulos MA
COVID-19是一种全球性大流行病，发病率和死亡率均有所上升。恢复期血浆（CP）输注是一种具有潜在治疗益处的策略。我们进行了一项多中心II期研究，以评估CP在4级或以上COVID-19患者中的疗效和安全性。为了评价CP的疗效，采用匹配倾向评分分析，将干预组（n = 59）与对照组（n = 59）进行比较。60例患者在症状发作后中位7天内接受CP治疗。在中位随访28.5天期间，56/60例患者完全康复，1例患者仍留在ICU。CP组的死亡率为3.4%，对照组为13.6%。通过多变量分析，CP接受者的死亡风险显著降低[HR：0.04（95% CI：0.004-0.36），p：0.005]，Kaplan-Meir分析显示总生存率显著提高（p < 0.001），拔管概率增加[OR：30.3（95% CI：2.64-348.9），p：0.006]。CP中较高水平的抗体与死亡风险显著降低独立相关。CP输注是安全的，只有1例3级不良事件（AE），很容易解决。早期使用CP可能是重度COVID-19患者的安全有效治疗（试验编号NCT 04408209）。
COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To evaluate the efficacy of CP, a matched propensity score analysis was used comparing the intervention (n = 59) to a control group (n = 59). Sixty patients received CP within a median time of 7 days from symptom onset. During a median follow-up of 28.5 days, 56/60 patients fully recovered and 1 patient remained in the ICU. The death rate in the CP group was 3.4% vs. 13.6% in the control group. By multivariate analysis, CP recipients demonstrated a significantly reduced risk of death [HR: 0.04 (95% CI: 0.004–0.36), p: 0.005], significantly better overall survival by Kaplan–Meir analysis (p < 0.001), and increased probability of extubation [OR: 30.3 (95% CI: 2.64–348.9), p: 0.006]. Higher levels of antibodies in the CP were independently associated with significantly reduced risk of death. CP infusion was safe with only one grade 3 adverse event (AE), which easily resolved. CP used early may be a safe and effective treatment for patients with severe COVID-19 (trial number NCT04408209).
登录
查看更多内容
严重的Covid-19患者急性呼吸窘迫综合征患者的康复血浆疗法的功效和安全性。
影响因子：
5.6
作者：
Allahyari A;Seddigh-Shamsi M;Mahmoudi M;Amel Jamehdar S;Amini M;Mozdourian M;Javidarabshahi Z;Eslami Hasan Abadi S;Amini S;Sedaghat A;Emadzadeh M;Moeini Nodeh M;Rahimi H;Bari A;Mozaheb Z;Kamandi M;Ataei Azimi S;Abrishami M;Akbarian A;Ataei P;Allahyari N;Hasanzadeh S;Saeedian N
通讯作者：
Saeedian N
DOI：
10.1007/s10096-004-1271-9
发表时间：
2005-01
期刊：
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
影响因子：
--
作者：
Cheng Y;Wong R;Soo YO;Wong WS;Lee CK;Ng MH;Chan P;Wong KC;Leung CB;Cheng G
通讯作者：
Cheng G
DOI：
10.1016/j.transci.2020.102955
发表时间：
2021-03
期刊：
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
影响因子：
--
作者：
Altuntas F;Ata N;Yigenoglu TN;Bascı S;Dal MS;Korkmaz S;Namdaroglu S;Basturk A;Hacıbekiroglu T;Dogu MH;Berber İ;Dal K;Kınık K;Haznedaroglu İ;Yılmaz FM;Kılıç İ;Demircioğlu S;Yosunkaya A;Erkurt MA;Turgut B;Caglayan M;Celik O
通讯作者：
Celik O
DOI：
10.1056/nejmoa2031893
发表时间：
2021-03-18
期刊：
The New England journal of medicine
影响因子：
--
作者：
Joyner MJ;Carter RE;Senefeld JW;Klassen SA;Mills JR;Johnson PW;Theel ES;Wiggins CC;Bruno KA;Klompas AM;Lesser ER;Kunze KL;Sexton MA;Diaz Soto JC;Baker SE;Shepherd JRA;van Helmond N;Verdun NC;Marks P;van Buskirk CM;Winters JL;Stubbs JR;Rea RF;Hodge DO;Herasevich V;Whelan ER;Clayburn AJ;Larson KF;Ripoll JG;Andersen KJ;Buras MR;Vogt MNP;Dennis JJ;Regimbal RJ;Bauer PR;Blair JE;Paneth NS;Fairweather D;Wright RS;Casadevall A
通讯作者：
Casadevall A
DOI：
10.1126/science.aan6836
发表时间：
2017-11-17
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Katzelnick LC;Gresh L;Halloran ME;Mercado JC;Kuan G;Gordon A;Balmaseda A;Harris E
通讯作者：
Harris E